Immuneering MAPKeeper-301 Phase 3 pancreatic cancer trial abstract wins ESMO 2026 poster slot
IMRX•Immuneering said its ongoing Phase 3 MAPKeeper-301 trial abstract will be presented at the ESMO Congress in Madrid on Oct. 25, 2026; the full abstract is scheduled for publication Oct. 19, and no clinical results were disclosed.
1. Trial abstract presentation
Immuneering said trial-in-progress details from its Phase 3 MAPKeeper-301 study of atebimetinib with chemotherapy in first-line metastatic pancreatic cancer will be presented at the ESMO Congress in Madrid on Oct. 25, 2026. The full abstract is scheduled for publication on Oct. 19. No clinical results were disclosed.
